DIVISLAB Divi's Laboratories Q4 FY25 results (Jan–Mar 2025) and concall
Divi's Labs delivered strong FY25 with 18% constant currency growth and significant margin expansion (EBITDA from 29% to 32%). Custom synthesis continues to gain share (54% of revenue) driven by strong RFP pipeline and two major long-term supply agreements worth ~₹700 crores each. Kakinada Phase 1 production commenced supporting backward integration. Company actively working on GLP-1, GIP, GLP-2 analogs and small molecules with multiple innovators across different development phases.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
| Line item | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|
| Revenue | 2,302 | 2,297 | 2,536 |
| EBITDA | 729 | 747 | 881 |
| Net profit | 518 | 594 | 667 |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
